Higher levels of urinary Bisphenol A (BPA), a chemical compound commonly used in plastic packaging for food and beverages, is associated with cardiovascular disease, type 2 diabetes and liver-enzyme abnormalities by up to 39%, according to a new study published in JAMA.

A study sponsored by Toronto, based Generex Biotechnology suggests that a novel glucose-delivering device, Glucose RapidSpray™, provides a higher degree of glycemic control in children with type 1 diabetes, as well as greater compliance.

Multisystemic therapy, an intensive home-based family therapy initiative, reduces hospital admissions for diabetic ketoacidosis in adolescents with poorly controlled type 1 diabetes, results of a new study recently published. 

Dialysis patients diagnosed with depression are nearly twice as likely to be hospitalized or die within a year than those who are not depressed, a UT Southwestern Medical Center researcher has found.

A diet filled with plenty of whole grains, fruits and vegetables, and low-fat dairy may help people lower their risk of type 2 diabetes, regardless of their race or ethnicity, a new study suggests.

Researchers say more effective control of blood fats, blood sugar, and blood pressure have contributed to recent declines in early mortality in people with type 2 diabetes.

Two weeks ago I wrote about the most promising new diabetes therapies and many of you wanted to know more so this week, Skott Lant, Doctor of Pharmacy Candidate UF College of Pharmacy has prepared a report on What Gpr119 is And How Compound Psn821 Might Work. This is a …

A 10-year follow-up of a landmark trial of intensive glucose control in type 2 diabetes has suggested that the clinical benefit was more than durable and rose over time to a reduction or 15% for myocardial infarction and a 13% reduction in the relative risk of death from any cause.

Type 2 diabetes patients treated with a once-weekly version of the incretin mimetic exenatide (Byetta) had better glycemic control than those given the injections twice a day, the standard approach, showed findings published online by The Lancet.

Bristol-Myers Squib and AstraZeneca’s experimental diabetes drug Onglyza significantly improves blood sugar control when added to older medicines, researchers said at EASD.